A team of investigators from Notre Dame has developed a blood-based test that they say can diagnose glioblastoma in less than an hour. The new diagnostic uses an electrokinetic technology that is capable of detecting epidermal growth factor receptors (EGFRs), which are known to be overexpressed in glioblastoma and other…

Guardant Health’s Shield blood test for colorectal cancer (CRC) screening was recently approved by the U.S. Food and Drug Administration (FDA). It’s indicated for people aged 45 and older who are at average risk for the disease. It is the first blood test to be approved by the FDA as…

Researchers at the Vall d’Hebron Institute of Oncology (VHIO) in Belgium, have developed a novel liquid biopsy methodology that enables the monitoring of disease evolution in patients with metastatic prostate cancer. The study, published in Cancer Cell, leverages the RNA contained in extracellular vesicles shed by tumor cells into the…

An artificial intelligence-powered tool for detecting circulating tumor DNA (ctDNA) in blood shows unprecedented sensitivity in predicting recurrence. In one case, the method (dubbed MRD-EDGE), detected five patients who had a colorectal-cancer recurrence, without any false negatives. MRD-EDGE, the researchers say, could improve cancer care with very early detection of…

Broadcast Date: June 10, 2024Time: 8:00 am PT, 11:00 am ET, 17:00 CET VIEW NOW Liquid biopsy research is a promising field of study that can potentially revolutionize the way we detect, diagnose, and treat diseases. Access to relevant specimens is an essential part of any discovery and development research program, but the…

Reporting in Science Advances, scientists at the Fred Hutchinson Cancer Center in Seattle have presented a blood-based test, known as liquid biopsy, capable of accurately distinguishing between types and subtypes of small cell lung cancer (SCLC), offering hope for precise diagnosis and personalized treatment plans for patients. SCLC, an aggressive…

Results of the IMvigor011 Phase III trial show that more than 90 percent of muscle invasive bladder cancer patients with a negative circulating tumor DNA (ctDNA) test following surgery, that remained negative at follow up, did not relapse. The results of the trial, presented today at the European Association of…

The use of liquid biopsies, particularly as a non-invasive diagnostic tool to detect cancer, has accelerated over the past ten years. While its applications in pathologies such as lung cancer or as a tool for detecting minimal residual disease (MRD) are well-documented, researchers continue to broaden its use in hard-to-detect…

A team of researchers from MIT and the Broad Institute of MIT and Harvard have established a way to significantly boost the sensitivity of liquid biopsies by delaying the clearance of circulating tumor (ct)DNA from the blood. They have developed two different types of injectable priming agents that transiently interfere…

The global liquid biopsy market is expected to exceed $18 billion by 2032, according to a new forecast from the market insights company Precedence Research. The growth will be driven by the aging population and the growing prevalence of cancer, the continued advancement of genomic technology, and an increased pipeline…

An international consortium of researchers, led by City of Hope and TGen, has been awarded a five-year, $4.5 million grant to validate a liquid biopsy for the early detection of pancreatic ductal adenocarcinoma (PDAC). The National Institutes of Health’s National Cancer Institute (NCI) awarded the grant to co-principal investigators Ajay…

Researchers at the Hospital for Sick Children (SickKids), the Ontario Institute for Cancer Research (OICR), and the University Health Network (UHN) have developed a liquid biopsy that an initial study has shown provides earlier detection cancer in individuals with Li-Fraumeni syndrome (LFS) than existing methods. LFS is hereditary disorder that…

A new liquid biopsy test developed by researchers at USC Norris Comprehensive Cancer Center has shown promise to distinguish which pelvic masses are benign and which are tumorous, a development that could aid early diagnosis of high-grade serous ovarian carcinoma (HGSOC), the most common and lethal form of the disease.…

In a new study presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting, researchers have confirmed the effectiveness of two liquid biopsy tests in identifying patients at high risk of cervical cancer recurrence after completing chemoradiation. The tests, a digital polymerase chain reaction (dPCR) and a sequencing test…

A novel liquid biopsy test has shown promise in revolutionizing the treatment approach for non-small cell lung cancer (NSCLC) that has spread beyond the lungs by identifying those patients that may benefit most from radiation treatments. The new data was released today in a presentation at the American Society for…